- Home
- RYTM vs ACLS Comparison
RYTM vs ACLS Comparison
Compare RYTM & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- ACLS
- Stock Information
- Founded
- RYTM 2008
- ACLS 1995
- Country
- RYTM United States
- ACLS United States
- Employees
- RYTM N/A
- ACLS N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- ACLS Industrial Machinery/Components
- Sector
- RYTM Health Care
- ACLS Technology
- Exchange
- RYTM Nasdaq
- ACLS Nasdaq
- Market Cap
- RYTM 3.1B
- ACLS 2.8B
- IPO Year
- RYTM 2017
- ACLS 2000
- Fundamental
- Price
- RYTM $59.94
- ACLS $75.07
- Analyst Decision
- RYTM Strong Buy
- ACLS Strong Buy
- Analyst Count
- RYTM 10
- ACLS 6
- Target Price
- RYTM $62.30
- ACLS $169.80
- AVG Volume (30 Days)
- RYTM 700.5K
- ACLS 755.5K
- Earning Date
- RYTM 11-05-2024
- ACLS 11-06-2024
- Dividend Yield
- RYTM N/A
- ACLS N/A
- EPS Growth
- RYTM N/A
- ACLS N/A
- EPS
- RYTM N/A
- ACLS 6.77
- Revenue
- RYTM $112,530,000.00
- ACLS $1,075,736,000.00
- Revenue This Year
- RYTM $63.95
- ACLS N/A
- Revenue Next Year
- RYTM $43.24
- ACLS $5.48
- P/E Ratio
- RYTM N/A
- ACLS $11.10
- Revenue Growth
- RYTM 81.55
- ACLS N/A
- 52 Week Low
- RYTM $31.53
- ACLS $69.35
- 52 Week High
- RYTM $68.58
- ACLS $158.61
- Technical
- Relative Strength Index (RSI)
- RYTM 57.57
- ACLS 32.86
- Support Level
- RYTM $58.00
- ACLS $69.35
- Resistance Level
- RYTM $60.79
- ACLS $85.88
- Average True Range (ATR)
- RYTM 3.33
- ACLS 3.47
- MACD
- RYTM -0.29
- ACLS -0.51
- Stochastic Oscillator
- RYTM 46.42
- ACLS 24.74
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provide aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services and customer training. Geographically, the group has a business presence in North America, Asia Pacific and Europe, of which key revenue is derived from the Asia Pacific.